Combat the spread of infectious disease
The past few months has shown that a team’s rapid response to expediting an assay globally, dedicated to the detection of SARS-CoV-2, is possible. BioGX, in a long-term partnership with Becton, Dickinson and Company, has submitted a test to the FDA for emergency use authorisation (EUA) in the US, in parallel to CE-IVD approval. In these challenging times, laboratories around the world have an urgent need for an easy-to-use, reliable test to detect SARS-CoV-2 to determine if patients have contracted COVID-19. Authorisation to use these tests worldwide would increase access to highly reliable results.